Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia

Cytokine

Volumn 62, Issue 3, 2013, Pages 439-445

  Ghalamfarsa, Ghasem ^a   Jadidi Niaragh, Farhad ^a   Hojjat Farsangi, Mohammad ^b   Asgarian Omran, Hossein ^a   Yousefi, Mehdi ^a   Tahmasebi, Fathollah ^a   Khoshnoodi, Jalal ^a   Razavi, Seyed Mohsen ^a   Saboor Yaraghi, Ali Akbar ^a   Rabbani, Hodjatallah ^c   Jeddi Tehrani, Mahmood ^c   Shokri, Fazel ^a,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

B cell proliferation; Chronic lymphocytic leukemia; CpG; Disease progression; Interleukin 21

Indexed keywords

INTERLEUKIN 21; TOLL LIKE RECEPTOR 9; CPG-OLIGONUCLEOTIDE; INTERLEUKIN DERIVATIVE; OLIGODEOXYRIBONUCLEOTIDE;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE; GENE MUTATION; HUMAN; IGHV GENE; IMMUNOPHENOTYPING; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; CASE CONTROL STUDY; DRUG EFFECTS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CELL PROLIFERATION; FEMALE; HUMANS; INTERLEUKINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES;

EID: 84877792944     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.03.023     Document Type: Article

References (44)

1. Ferrarini M., Chiorazzi N. Recent advances in the molecular biology and immunobiology of chronic lymphocytic leukemia. Semin Hematol 2004, 41:207-213.
2. Caligaris-Cappio F., Hamblin T.J. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999, 17:399-408.
3. Hojjat-Farsangi M., J-T M., Razavi S.M., Sharifian R.A., Mellstedt H., Shokri F., et al. Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia. Cancer Sci 2009, 12:2346-2353.
4. Kay N.E., O'brien S.M., Pettitt A.R., Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia 2007, 21:1885-1891.
5. Orchard J.A., Ibbotson R.E., Davis Z., Wiestner A., Rosenwald A., Thomas P.W., et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004, 363:105-111.
6. Thunberg U., Johnson A., Roos G., Thorn I., Tobin G., Sallstrom J., et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 2001, 97:1982-1994.
7. Sagatys E.M., Zhang L. Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia. Cancer Control 2012, 19:18-25.
8. Bouley J., Deriano L., Delic J., Merle-Beral H. New molecular markers in resistant B-CLL. Leuk Lymphoma 2006, 47:791-801.
9. Binet J.-L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariable survival analysis. Cancer 1981, 48:198-206.
10. Rai K., Sawitsky A., Cronkite E., Chanana A., Levy R., Pasternak B. Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46:219-234.
11. Moreno C., Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008, 22:211-219.
12. Rassenti L.Z., Jain S., Keating M.J., Wierda W.G., Grever M.R., Byrd J.C., et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008, 112:1923-1930.
13. Jadidi-Niaragh F., Yousefi M., Memarian A., Hojjat-Farsangi M., Khoshnoodi J., Razavi S.M., et al. Increased frequency of CD8(+) and CD4(+) regulatory T cells in chronic lymphocytic leukemia: association with disease progression. Cancer Invest 2013, 31:121-131.
14. Jadidi-Niaragh F., Ghalamfarsa G., Memarian A., Asgarian-Omran H., Razavi S.M., Sarrafnejad A., et al. Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia. Tumor Biol 2012, 34:929-940.
15. Jadidi-Niaragh F., Jeddi-Tehrani M., Ansaripour B., Razavi S.M., Sharifian R.A., Shokri F. Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia. Med Oncol 2012, 29:3561-3569.
16. Christopoulos P., Pfeifer D., Bartholomé K., Follo M., Timmer J., Fisch P., et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood 2011, 117:3836-3846.
17. Zaknoen S., Kay N. Immunoregulatory cell dysfunction in chronic B-cell leukemias. Blood Rev 1990, 4:165-174.
18. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57-63.
19. Nurieva R., Yang X.O., Martinez G., Zhang Y., Panopoulos A.D., Ma L., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
20. Coquet J.M., Kyparissoudis K., Pellicci D.G., Besra G., Berzins S.P., Smyth M.J., et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007, 178:2827-2834.
21. Mehta D.S., Wurster A., Grusby M.J. Biology of IL-21 and the IL-21 receptor. Immunol Rev 2004, 202:84-95.
22. Good K.L., Bryant V.L., Tangye S.G. Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21. J Immunol 2006, 177:5236-5247.
23. de Totero D., Meazza R., Zupo S., Cutrona G., Matis S., Colombo M., et al. Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood 2006, 107:3708-3715.
24. Gowda A., Roda J., Hussain S.R., Ramanunni A., Joshi T., Schmidt S., et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 2008, 111:4723-4730.
25. Spolski R., Leonard W. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol 2008, 20:295-301.
26. Jahrsdorfer B., Jox R., Muhlenhoff L., et al. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 2002, 72:83-92.
27. Krieg A.M., Yi A., Matson S., et al. CpG motifs is bacterial DNA trigger direct B cell activation. Nature 1995, 374:4.
28. Jahrsdorfer B., Hartmann G., Racila E., et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001, 69:81-88.
29. Jahrsdorfer B., Mühlenhoff L., Blackwell S.E., et al. B cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005, 11:1490-1499.
30. Jahrsdorfer B., Wooldridge J., Blackwell S.E., et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2005, 77:378-387.
31. Longo P.G., Laurenti L., Gobessi S., Petlickovski A., Pelosi M., Chiusolo P., et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2007, 21:110-120.
32. Jahrsdörfer B., Blackwell S., Wooldridge J.E., Huang J., Andreski M.W., Jacobus L.S., et al. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 2006, 108:2712-2719.
33. Jaffe E.S. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology 2009, 2009:523-531.
34. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Döhner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
35. Cheson B.D., Bennett J.M., Grever M., Kay N., Keating M.J., O'Brien S., et al. National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87:4990-4997.
36. Gharagozlou S., ALIK GHOLAM, Rabbani H., Shokri F. Molecular analysis of the heavy chain variable region genes of human hybridoma clones specific for coagulation factor VIII. Thrombosis and haemostasis. 2005, 94:1131-1137.
37. Kazemi T., Asgarian-Omran H., Hojjat-Farsangi M., Shabani M., Memarian A., Sharifian R.A., et al. Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia. Int J Cancer 2008, 123:2113-2119.
38. Younesi V., Nikzamir H., Yousefi M., Khoshnoodi J., Arjmand M., Rabbani H., et al. Epstein Barr virus inhibits the stimulatory effect of TLR7/8 and TLR9 agonists but not CD40 ligand in human B lymphocytes. Microbiol Immunol 2010, 54:534-541.
39. Decker T., Schneller F., Sparwasser T., et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000, 95:8.
40. Krieg A.M., Yi A., Matson S., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
41. Jahrsdorfer B., Blackwell S.E., Wooldridge J.E., Huang J., Andreski M.W., Jacobus L.S., et al. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 2006, 108:2712-2719.
42. Jahrsdorfer B., Wooldridge J.E., Blackwell S.E., Taylor C.M., Griffith T.S., Link B.K., et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukocyte Biol 2005, 77:378.
43. Ma J., Ma D., Ji C. The role of IL-21 in hematological malignancies. Cytokine 2011, 56:133-139.
44. Jin H., Carrio R., Yu A., Malek T.R. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol 2004, 173:8.